Effects of iguratimod on the levels of circulating regulators of bone remodeling and bone remodeling markers in patients with rheumatoid arthritis

被引:0
|
作者
Xuetong Wang
Cuili Ma
Ping Li
Feng Zhao
Liqi Bi
机构
[1] China-Japan Union Hospital of Jilin University,Department of Rheumatology and Immunology
来源
Clinical Rheumatology | 2017年 / 36卷
关键词
Bone remodeling markers; Iguratimod; Methotrexate; Regulators of bone remodeling; Rheumatoid arthritis;
D O I
暂无
中图分类号
学科分类号
摘要
This study aims to investigate the effect of iguratimod, a novel disease-modifying antirheumatic drug, alone or combined with methotrexate (MTX), on the serum levels of regulators of bone remodeling (receptor activator of nuclear factor-κB ligand (RANKL), osteoprotegerin (OPG), and Dickkopf-1 (DKK-1)) and bone remodeling markers (C-telopeptide of type I collagen (CTX-I) and procollagen type I N-terminal propeptide (PINP)) in patients with rheumatoid arthritis (RA). Patients with RA were treated with iguratimod, MTX, or their combination for 12 months. Serum samples were collected before treatment and 6 and 12 months afterwards. RANKL, OPG, DKK-1, CTX-I, and PINP levels were measured, and radiographic progression was assessed. The serum RANKL levels decreased after treatment for 6 and 12 months with iguratimod (median: baseline 565.00 pmol/L vs. 6 months 411.00 pmol/L vs. 12 months 212.00 pmol/L), MTX (median: baseline 562.50 pmol/L vs. 6 months 399.50 pmol/L vs. 12 months 163.50 pmol/L), and their combination (median: baseline 971.00 pmol/L vs. 6 months 272.50 pmol/L vs. 12 months 241.50 pmol/L). Combination therapy showed greater effects 6 months post-treatment compared to single-drug therapy. PINP levels increased significantly 12 months post-treatment with all therapies, but only the combination therapy led to decreased CTX-I levels. OPG and DKK-1 levels showed no significant changes. The three treatments showed no significant differences in radiographic progression. Iguratimod could stimulate bone formation and regulate the RANKL/RANK/OPG system rather than DKK-1levels. Its effects are comparable to those of MTX, and combination therapy showed stronger effects.
引用
收藏
页码:1369 / 1377
页数:8
相关论文
共 50 条
  • [21] BONE REMODELING IN OSTEOPOROSIS ASSOCIATED WITH RHEUMATOID-ARTHRITIS
    KROGER, H
    ARNALA, I
    ALHAVA, EM
    CALCIFIED TISSUE INTERNATIONAL, 1991, 49 : S90 - S90
  • [22] Effects of infliximab on bone turnover markers in patients with rheumatoid arthritis: Improvement of bone remodeling balance and differential effects on cathepsin K and matrix-metalloproteases mediated bone resorption
    Thomas, T
    le Henanff, A
    Debiais, F
    Daragon, A
    Roux, C
    Sany, J
    Wendling, D
    Zarnitsky, C
    Ravaux, P
    Garnero, P
    ARTHRITIS AND RHEUMATISM, 2005, 52 (09): : S143 - S143
  • [23] Effects of zoledronic acid on serum levels of MMPs and bone remodeling markers in breast cancer patients with bone metastases
    Kanakis, I
    Nikolaou, M
    Kiamouris, C
    Pectasides, D
    Karamanos, N
    FEBS JOURNAL, 2005, 272 : 270 - 270
  • [24] Bone status in patients with epilepsy: relationship to markers of bone remodeling
    Hamed, Sherifa A.
    Moussa, Ehab M. M.
    Youssef, Ahmad H.
    Abd ElHameed, Mohammed A.
    NasrEldin, Eman
    FRONTIERS IN NEUROLOGY, 2014, 5
  • [25] Effects of infliximab on bone turnover markers in patients with rheumatoid arthritis: Improvement of bone remodeling balance and differential effects on cathepsin K and matrix-metalloproteases mediated bone resorption.
    Thomas, T
    le Henanff, A
    Debiais, F
    Daragon, A
    Roux, C
    Sany, J
    Wendling, D
    Zarnitsky, C
    Ravaux, P
    Garnero, P
    JOURNAL OF BONE AND MINERAL RESEARCH, 2005, 20 (09) : S305 - S305
  • [26] MARKERS OF BONE REMODELING IN PATIENTS TAKING GLUCOCORTICOIDS
    LUKERT, BP
    HIGGINS, J
    JOURNAL OF BONE AND MINERAL RESEARCH, 1995, 10 : S181 - S181
  • [27] Influence of Rituximab on markers of bone remodeling in patients with rheumatoid arthritis: a prospective open-label pilot study
    Gert Hein
    Thorsten Eidner
    Peter Oelzner
    Michael Rose
    Alexander Wilke
    Gunter Wolf
    Sybille Franke
    Rheumatology International, 2011, 31 : 269 - 272
  • [28] Influence of Rituximab on markers of bone remodeling in patients with rheumatoid arthritis: a prospective open-label pilot study
    Hein, Gert
    Eidner, Thorsten
    Oelzner, Peter
    Rose, Michael
    Wilke, Alexander
    Wolf, Gunter
    Franke, Sybille
    RHEUMATOLOGY INTERNATIONAL, 2011, 31 (02) : 269 - 272
  • [29] The effects of iguratimod combined with methotrexate and hydroxychloroquine on bone mineral density in patients with rheumatoid arthritis
    Yu, Jing-Jing
    Wu, Fei
    Ma, Rui-Rui
    Wu, Tian-Jin
    Zhang, Yuan
    Ying, Zhen-Hua
    PHARMAZIE, 2021, 76 (10): : 507 - 510
  • [30] RADIOACTIVE MARKERS AND BONE REMODELING
    JEE, WSS
    ANATOMICAL RECORD, 1961, 139 (02): : 241 - &